Literature DB >> 1530827

Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma.

D S Robinson1, Q Hamid, S Ying, A Tsicopoulos, J Barkans, A M Bentley, C Corrigan, S R Durham, A B Kay.   

Abstract

BACKGROUND: In atopic asthma, activated T helper lymphocytes are present in bronchial-biopsy specimens and bronchoalveolar-lavage (BAL) fluid, and their production of cytokines may be important in the pathogenesis of this disorder. Different patterns of cytokine release are characteristic of certain subgroups of T helper cells, termed TH1 and TH2, the former mediating delayed-type hypersensitivity and the latter mediating IgE synthesis and eosinophilia. The pattern of cytokine production in atopic asthma is unknown.
METHODS: We assessed cells obtained by BAL in subjects with mild atopic asthma and in normal control subjects for the expression of messenger RNA (mRNA) for interleukin-2, 3, 4, and 5, granulocyte-macrophage colony-stimulating factor (GM-CSF), and interferon gamma by in situ hybridization with 32P-labeled complementary RNA. Localization of mRNA to BAL T cells was assessed by simultaneous in situ hybridization and immunofluorescence and by in situ hybridization after immunomagnetic enrichment or depletion of T cells.
RESULTS: As compared with the control subjects, the subjects with asthma had more BAL cells per 1000 cell that were positive for mRNA for interleukin-2 (P less than 0.05), 3 (P less than 0.01), 4 (P less than 0.001), and 5 (P less than 0.001) and GM-CSF (P less than 0.001). There was no significant difference between the two groups in the number of cells expressing mRNA for interferon gamma. In the subjects with asthma, mRNA for interleukin-4 and 5 was expressed predominantly by T lymphocytes.
CONCLUSIONS: Atopic asthma is associated with activation in the bronchi of the interleukin-3, 4, and 5 and GM-CSF gene cluster, a pattern compatible with predominant activation of the TH2-like T-cell population.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1530827     DOI: 10.1056/NEJM199201303260504

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  602 in total

Review 1.  Immune mechanisms of childhood asthma.

Authors:  C E Donovan; P W Finn
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

Review 2.  Airway remodeling in asthma.

Authors:  J A Elias; Z Zhu; G Chupp; R J Homer
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

Review 3.  Th2 cells and GATA-3 in asthma: new insights into the regulation of airway inflammation.

Authors:  A Ray; L Cohn
Journal:  J Clin Invest       Date:  1999-10       Impact factor: 14.808

4.  Kinetics of GATA-3 gene expression in early polarizing and committed human T cells.

Authors:  E Lantelme; S Mantovani; B Palermo; R Campanelli; F Sallusto; C Giachino
Journal:  Immunology       Date:  2001-02       Impact factor: 7.397

Review 5.  Cytokines in asthma.

Authors:  K F Chung; P J Barnes
Journal:  Thorax       Date:  1999-09       Impact factor: 9.139

6.  Clonal expansion of T cells infiltrating in the airways of non-atopic asthmatics.

Authors:  T Umibe; Y Kita; A Nakao; H Nakajima; T Fukuda; S Yoshida; T Sakamaki; Y Saito; I Iwamoto
Journal:  Clin Exp Immunol       Date:  2000-03       Impact factor: 4.330

Review 7.  Th1/Th2 balance in atopy.

Authors:  T Biedermann; M Röcken
Journal:  Springer Semin Immunopathol       Date:  1999

Review 8.  Airway hyperresponsiveness in asthma: not just a matter of airway inflammation.

Authors:  V Brusasco; E Crimi; R Pellegrino
Journal:  Thorax       Date:  1998-11       Impact factor: 9.139

Review 9.  Modulation of asthmatic response by immunostimulatory DNA sequences.

Authors:  D Broide; J Y Cho; M Miller; J Nayar; G Stachnick; D Castaneda; M Roman; E Raz
Journal:  Springer Semin Immunopathol       Date:  2000

Review 10.  Allergen immunotherapy: does it work and, if so, how and for how long?

Authors:  D S Robinson
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.